جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

2 مُخرَج نتائج البحث عن «Logistic regression»

نسخة أوليةمفتوح (مستودع)20231استشهاد

A large proportion of a Saudi population with type 2 diabetes mellitus was found to be non-adherent to antidiabetics: a retrospective cohort study

—

Purpose: Optimal adherence to antidiabetics among patients with type 2 diabetes mellitus has been associated with positive health outcomes; however, studies to assess this adherence in Saudi Arabia are scarce. We aimed to evaluate adherence to antidiabetics using a Saudi population. Methods: This was a multicenter, retrospective cohort study of patients (≥ 18 years old) with type 2 diabetes mellitus who received ≥ 1 antidiabetic between 2015 and 2020. Adherence was estimated using the continuous multiple-interval measure of medication availability (CMA7). A CMA7 cutoff point of ≥ 80% was chosen to define optimal adherence, and the odds of not achieving therapeutic annual HbA1c levels (i.e. ≥ 7%) in the optimal vs. suboptimal adherence groups was assessed using a logistic regression model adjusting for the measured confounders. Results: A total of 36,789 patients were included in the study. The most commonly prescribed regimens were metformin single treatment (n=15,025 [41.6%]) and gliclazide-metformin combination treatment (n=5,667 [15.7%]). The median CMA7 was 70.4%, and only 13,552 (36.9%) patients were adherent to their antidiabetics (CMA7 ≥ 80%). The odds of not achieving therapeutic HbA1c levels one year after the index date were comparable in the optimal vs. suboptimal adherence groups (odds ratio = 0.99, 95% confidence interval 0.92 to 1.05). Conclusions: This study showed that a large proportion of a Saudi population with type 2 diabetes mellitus were non-adherent to their antidiabetic treatments. Future Saudi and regional studies are needed to assess the impact of adherence on HbA1c levels and on cardiovascular outcomes.

type 2 diabetesantidiabetic medication adherencemedication non-adherenceHbA1c control
نسخة أوليةمفتوح (مستودع)2020

Severity of COVID-19 Infection in ACEI/ARB Users in Two Saudi Public Specialty Hospitals: Retrospective Cohort Study

Research Square

Abstract Background: The uncertainty about COVID-19 outcomes in angiotensin converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) users continues with contradictory findings. The aim of this study was to determine the effect of ACEI/ARB use in patients with severe COVID-19. Methods: This retrospective cohort study was done in two Saudi public specialty hospitals designated as COVID-19 referral facilities. We included 354 patients with confirmed diagnosis of COVID-19 between April and June 2020, of which 146 were ACEI/ARB users and 208 were non-ACEI/ARB users. Controlling for confounders, we conducted a multivariate logistic regression and a sensitivity analyses using propensity score matching (PSM) and Inverse propensity score weighting (IPSW) for high risk patient subsets. Results: Compared to non-ACEI/ARB users, ACEI/ARB users had an eight-fold higher risk of developing critical or severe COVID-19 (OR=8.25, 95%CI=3.32-20.53); a nearly 7-fold higher risk of intensive care unit (ICU) admission (OR=6.76, 95%CI=2.88-15.89) and a nearly 5-fold higher risk of requiring noninvasive ventilation (OR=4.77,95%CI=2.15-10.55). Patients with diabetes, hypertension, and/or renal disease had a five-fold higher risk of severe COVID-19 disease (OR=5.40,95%CI=2.0-14.54]. These results were confirmed in the PSM and IPSW analyses. Conclusion: In general, but especially among patients with hypertension, diabetes, and/or renal disease, ACEI/ARB use is associated with a significantly higher risk of severe or critical COVID-19 disease, and ICU care.

COVID-19 pandemicACE inhibitorsangiotensin receptor blockerssevere COVID-19